Home
>
US Stocks
>
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
ZNTL

Zentalis Pharmaceuticals Inc

$74.9618.98%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
78.82
Today Low/High
74.96 / 78.82
52 Week Low/High
$25.41 / $62.79
Market Cap
$2.42B

Company Details

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.
Organisation
Zentalis Pharmaceuticals Inc
Employees
124
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Zentalis Pharmaceuticals Inc share price today

Can Indians buy Zentalis Pharmaceuticals Inc shares?

How can I buy Zentalis Pharmaceuticals Inc shares from India?

Can Fractional shares of Zentalis Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Zentalis Pharmaceuticals Inc stocks?

We are a SEBI registered investement advisor